(24/7 MARKET NEWS) – ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) announced, after yesterday’s market close, that it entered into a clinical development collaboration for a potential Phase 2 study of ORIC-533 in multiple myeloma with Pfizer and agreed to sell 5,376,344 of its common shares at a price of $4.65 per share to Pfizer for approximately $25 million in proceeds.
Oric Pharma is trading higher in this morning’s premarket, at $4.35, up $1.35 (+45.00%), on 3.7 million shares traded.
Its 52-week range is $2.36 to $17.26. Its next inflection points are $5.12, today’s premarket high, and $5.50. If it can break through the $5.50 resistance level, on strong volume, it has a favorable setup for a potential run to much higher levels.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
